Register before 23rd August & Save up to £300

23rd-25th October, 2019 | London, UK

www.nash-europe.com

3rd Annual

NASH Summit 2019 EUROPE

Deepen Understanding of the Role of Liver Fibrosis in NASH, Confidently Meet Regulatory Guidelines & Define Clinical Trial Endpoints

Keynote Speakers:

Frank Anania
Divsision of Gastroenterology & Inborn Errors Products
FDA

Vincenzo Costigliola
Founder & President
European Medical Association (EMA)

Massimo Pinzani
Professor of Medicine
UCL

Plus 27 other expert speakers including:

Giampiero "GP" Carlo
Head of Brand: Cotadutide Cardiovascular, Renal & Metabolism (CVRM)
AstraZeneca

Nikolai Naoumov
Executive Director, Hepatology Sciences & Innovation
Novartis

Jeanette Kusel
Director Scientific Advice
National Institute for Health & Care Excellence (NICE)

Livia Alimenia
European Office Director
Global Liver Institute

Richard Torstenson
Director International Clinical Development NASH
Allergan

Partner: METABOLON

Tel: +44 (0)20 3141 8700 **Email:** Info@hansonwade.com

hansonwade

Welcome to Europe's Gathering of NASH Drug Developers

Harness *ex vivo* innovations, understand developments in serum biomarkers & establish the needs of European doctors

Now in its 3rd year, the **NASH Summit Europe** is the definitive forum for Europe's NASH drug development strategy.

Developed alongside 25+ thought leaders from expert organisations including **Genfit**, **Intercept**, **Gilead**, and the **FDA**, this discussion based, intimate conference will enable you to more robustly evaluate candidates in preclinical human context, goal set in medical care and advance your pipeline towards patient goals.

Uniting **80+ senior NASH drug development stakeholders**, join us to keep pace with the rapidly progressing NASH field, benchmark your progress against your competitors and build connections to enable you to bypass your drug development roadblocks.

What Can You Expect?

- **80+** Attendees
- **50+** Organisations
- **7** Panel Discussions
- **27** Expert Speakers
- **1** Poster Session
- **2** Workshops

"This was my first NASH Summit but certainly not my last"

Robert Arch
Executive Director; Head, Liver Disease Program
China, Novartis Institute for BioMedical Research
(Speaker, 3rd NASH Summit, Boston, 2019)

"The NASH Summit brought a wide range of stakeholders from bench to bedside to the discussion. It had excellent organization with unique networking opportunities"

Resat Cinar
Co-Chair NIH Fibrosis Scientific Interest Group
National Institutes of Health
(Speaker 3rd NASH Summit, Boston, 2019)

Your Top 5 Takeaways From Key Stakeholders

1

Understand Health Technology Assessment Bodies Perspectives

Understand protocol for payer's decisions and expert thoughts on pricing and reimbursement with **NICE** and **AstraZeneca** to better inform your early pipeline decisions

2

Understand How Big Pharma Are Looking at NASH & Combinations

Evaluate combinations of NASH candidates with **Novartis** to understand considerations for synergistic effectiveness, and understand partnership decision making with **Merck** to inform your own candidate's combination potential

3

Critically Address the Bench to Bedside Translational Gap

Evaluate *ex vivo* modalities to better predict drug efficacy, navigate NASH pathogenesis, and computational charting of metabolic processes with **LiSyM** to better evaluate liver fibrosis non-invasively

4

Contextualise Regulatory Guidance for NASH with Compensated Cirrhosis

Understand the narrative behind regulatory guidance for NASH with the **FDA** and analyse clinical trial design post NASH treatment approval with **Allergan** to better design and execute your own trials

5

Delineate NASH Pathophysiology to Develop More Effective Drug Candidates

Develop understanding of the role of liver fibrosis with **UCL** and **Newcastle University** to determine NASH progression and mortality and help you to better stratify NASH populations

Why Industry Attends The NASH Summit

"This was my first **NASH** meeting and proved to be a very valuable experience, bringing me up to speed on what is happening in the field and areas of unmet need. It was also great for networking"

Takeda

"The **NASH Summit** is a pre-eminent meeting which everyone with an interest in NASH should attend. The science, insights into future developments and networking opportunities are outstanding"

novo nordisk

"The **NASH Summit** provided a great opportunity and collaborative forum to learn from the experiences of drug developers in the space and apply these to the evolution of future development programs."

HIGHTIDE

"Excellent summit: condensed efficient way to learn latest advancements in **NAFLD/NASH** diagnosis and therapy & connect with like-minded business leaders. Keep up the good work!"

PHILIPS Healthcare

"Even when I hear talks from people I already know at the **NASH Summit** - I still come away with new information. It is amazing how much you can take away from this conference"

GENFIT
TOWARDS BETTER MEDICINE

"The **NASH Summit** was one of the best scientific conferences with regard to the information and quality of scientific presentations and the ability to network directly with pharma and colleagues"

ERG

Your Expert Speakers

Your Keynotes:

Frank Anania
Division of Gastroenterology & Inborn Errors Products
FDA

Massimo Pinzani
Professor of Medicine
UCL

Vincenzo Costigliola
Founder & President
European Medical Association (EMA)

Your 27 other expert speakers:

Achim Kautz
Founder
Leberhilfe Projekt

Bevin Gangadharan
Research Associate
University of Oxford

Christine Reynet
Director
McC+R&D Consulting

Daren Ure
Director of Research & Development
ContraVir Pharmaceuticals

David Blakey
Chief Scientific Officer
MiNA Therapeutics

Elias Papatheodorou
Chief Executive Officer
Genkyotex

Felix Yeh
Scientist
Genentech

Giampiero "GP" Carlo
Head of Brand: Cotadutide, Cardiovascular, Renal & Metabolism (CVRM)
AstraZeneca

Ian Rowe
University Academic Fellow & Hepatologist
University of Leeds

Jacobo Miranda
Postdoctoral Researcher Collaborator
LiSyM

Jeanette Kusel
Director Scientific Advice
National Institute for Health & Care Excellence (NICE)

Jelena Mann
Professor of Epigenetics
Fibrosis Research Group Newcastle University

John O'Neil
Chief Scientific Officer
XYLYX

Kari Wong
Senior Study Director
Metabolon

Livia Alimenia
European Office Director
Global Liver Institute

Your Expert Speakers

Marc Hertz
Chief Executive Officer
GRI Bio

Marian McNeil
Chief Operating Officer
Stratified Medicine Scotland Innovation Centre

Michel de Baar
Executive Director – Business Development, Licensing, Infectious Diseases, Vaccines, Cardiovascular & Metabolic Diseases
MSD

Naim Alkhouri
Director of the Metabolic Health Centre
Texas Liver Institute

Nicolas Guisot
Research Fellow
RedX Pharma

Nikolai Naoumov
Executive Director, Hepatology Sciences & Innovation
Novartis

Olga Vvedenskaya
Postdoctoral Researcher Member
LiSyM

Peter Traber
Partner
Alacrita Consulting

Richard Torstenson
Director International Clinical Development NASH
Allergan

Tariq Sethi
Co-founder
Galecto Biotech

Thomas Baumert
Professor of Medicine, Institute of Viral & Liver Disease
Inserm

Trent Ross
Principal Scientist, Metabolism
Pfizer

"Very informative meeting in a friendly atmosphere to get a nice overview on the activities in NASH disease"

Poxel Pharmaceuticals
(Speaker, 2nd NASH Summit Europe, 2018)

"It was great pleasure to be part of such an event. Great mix of industria and academia and very high quality presentations"

Kings College London
(Speaker, 2nd NASH Summit Europe, 2018)

Pre-Conference Workshop Day
Wednesday, 23rd October 2019

Workshop A
9.00 - 12.00

Stratification of NASH Through Patient Data Sets

Between 2015 and 2030 the prevalence of NASH is expected to rise by 63% (Estes 2018), exacerbating the existing challenge of stratifying and annotating a heterogeneous and largely asymptomatic population. Stratified Medicine Scotland – Innovation Centre (SMS-IC) is focused on linking Scotland's domain expertise, data assets and delivery capability to accelerate the adoption of Precision Medicine within NASH for more effective medicine development, better diagnostics and earlier intervention, and optimal treatment selection.

This workshop will give you a deep dive into:

- The construction of highly curated and annotated patient data sets
- Accessing the right patient populations for stratification
- Ensuring data quality and content

Workshop Leader

Marian McNeil
Chief Operating Officer
Stratified Medicine Scotland Innovation Centre

Workshop B
13.00 - 16.00

Computational Models to Facilitate Drug Decision Making in NASH

Researching computation charting of metabolic paths in the liver, developing multiscale three-dimensional imaging of pathological features and metabolic derangements, multimodal modelling and charting of metabolic processes hold potential to yield new insights and new drugs for NAFLD/NASH.

In this workshop we will address:

- The kind of data that can be obtained by mass spectrometry (MS) from human liver samples (both biopsies and surgery material) and how these data can be helpful to the MDs
- The main challenges in establishing a working collaboration with all the partners from the different relevant disciplines (medical doctors, wet lab scientists, dry lab scientists, modeling team)
- Techniques for sample analysis with MS adopting examples from our current work (shotgun lipidomics analysis of LiSyM samples from the Kiel cohort)
- Data analysis, visualization, integration and delivery to medical partners

Workshop Leaders

Jacobo Miranda
Postdoctoral Researcher Collaborator
LiSyM

Olga Vvedenskaya
Postdoctoral Researcher Member
LiSyM

Welcome Evening
Wednesday 23rd October 2019

Novel Target Identification & Early Stage Results

Christine Reynet
Director
McC+R&D Consulting

16.30 Current and Emerging Approaches for NASH Drug Development

- Approaches developed for treating NASH and current drugs in clinical trials
- Overview of emerging therapeutic targets
- Key challenges into the understanding and treatment of NASH

Daren Ure
Director of Research & Development
ContraVir Pharmaceuticals

16.50 CRV431, A Novel Drug Candidate for Liver Fibrosis

- Cyclophilin inhibition attenuates many pathological mechanisms
- CRV431 reduces fibrosis in multiple experimental models
- CRV431 appears best suited for late stages of hepatitis of diverse etiologies

David Blakey
Chief Scientific Officer
MiNA Therapeutics

17.10 Small activating RNA (saRNA) Platform for NASH/Fibrosis Targets

- Providing data demonstrating saRNA is a clinically validated platform to upregulate target gene expression
- Demonstrating application of saRNA platform for NASH targets and discuss liver delivery
- Sharing new *in vitro* and *in vivo* data on HNF4a saRNA as a novel therapeutic approach for NASH

Marc Hertz
Chief Executive Officer
GRI Bio

17.30 NKT Cells and their role in NASH as a Therapeutic Target

- Introducing type I invariant NKT (NKT 1) cells and their role in inflammation and fibrotic disease with evidence from human studies in chronic liver disease
- Discussing pathogenic NKT cells as a biomarker of fatty liver disease and potential to distinguish patients with advanced NASH (NAS4+) with significant fibrosis (F3+)
- Presenting data on GRI-0621, an inhibitor of NKT 1 cells from a Phase 2a study in chronic liver disease patients and planned future studies

17.50 Combination Therapies for NASH from the Biotech Perspective

- Panel Discussion & Q&A with Preceding Speakers

18.20 Drinks Reception & Networking

> "This was a very informative conference that provided a great opportunity to network with top thought leaders and researchers in NASH"
>
> **Merck**

Conference Day One
Thursday 24th October 2019

Peter Traber Partner **Alacrita Consulting**	**7.50**	**Chair's Opening Remarks**

The Mouse in the Room: How can we Push Preclinical Models to be Better?

Massimo Pinzani Professor of Medicine **UCL**	**8.00**	**Advanced *In-Vitro* Modelling of Liver Fibrosis** • Using tissue engineering for drug target discovery and non-invasive evaluation of liver fibrosis • Further session details to follow
Jelena Mann Professor of Epigenetics **Fibrosis Research Group Newcastle University**	**8.20**	**Using Precision Cut Liver Slices to Model Fibrosis** • Sharing data on testing the ability of clinically approved drugs to limit fibrosis in this model and how this new bioreactor can be successfully used to model fibrogenesis and demonstrate efficacy of anti-fibrotic therapies • Demonstrating the utility of precision cut liver slices (PCLS) retaining the structure and cellular composition of the native liver • Showcasing the FibroFind bioreactor system that increases the healthy lifespan of PCLS which allows us to model fibrogenesis
Thomas Baumert Professor of Medicine, Institute of Viral & Liver Disease **Inserm**	**8.40**	**Drug Discovery for NASH & Liver Fibrosis Using Human Cell-Based Models** • Appreciating the discovery of compounds for treatment of advanced liver disease has been hampered by tractable and model systems for disease biology • Sharing human cell based model that mimics gene expression in patients with NASH and advanced liver disease for fast-track discovery of liver disease therapeutics • Using the model system to identify several novel targets and compounds with completed *in vivo* proof-of-concept
John O'Neil Chief Scientific Officer **XYLYX**	**9.00**	**Disease-Specific Extracellular Matrix Cell Culture Substrates to Improve Predictive in Vitro Models of NASH** • Development of a standardized, fully humanized commercial 3D cell culture platform for NASH research comprised of extracellular matrix (ECM) that recapitulates the human NASH disease environment in vitro • To reduce the dependence on animal models, and enable more relevant scientific results leading to improved drug discovery process
	**9.15**	**Are we able to Standardise & Improve Preclinical Models?** • Panel Discussion & Q&A with Preceding Speakers
	**9.45**	**Speed Networking** This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the NASH field and establish meaningful business relationships.
	10.15	**Morning Break**

Deepening Understanding of Liver Fibrosis: Drivers, Targets & Predictors of Progression

Jelena Mann Professor of Epigenetics **Fibrosis Research Group Newcastle University**	**11.00**	**Delineating & Utilising the Complexities of Fibrosis Pathology** • Evaluating epigenetic mechanisms governing liver fibrogenesis, both in rodent models of disease and in patients • Determining grade of fibrosis using hepatic DNA methylation signatures present in the circulating cell-free DNA • Describing DNA methylation-histone modification nodes that regulate myofibroblast phenotype and fibrogenesis and how targeted delivery of epigenetic drugs to HSC has therapeutic potential

Elias Papatheodorou
Chief Executive Officer
Genkyotex

11.20 Importance of Fibrosis for NASH Therapy

- Targeting multiple fibrogenic pathways with the NOX1/4 inhibitor GKT831
- Exploring GKT831's mechanism of action - targeting multiple fibrogenic pathways
- Comprehensively reviewing understanding of clinical efficacy and safety profiles in liver, lung and kidney fibrosis

11.40 Targeting Liver Fibrosis with New Generation Drugs

- Panel Discussion & Q&A with Preceding Speakers

12.00 Lunch & Networking

Validating Biomarkers Against Liver Histology

Kari Wong
Senior Study Director
Metabolon

13.30 Precision Metabolomics: Understanding the Complexity of NAFLD/NASH

- Understanding Metabolon's Precision Metabolomiics technology: a mass spectrometry-based method that allows for the identification small molecule compounds in a single sample
- Surveying diverse metabolic pathways simultaneously in a single sample
- Demonstrating a holistic assessment of NAFLD/NASH complexity

Bevin Gangadharan
Research Associate
University of Oxford

13.50 Novel Serum Biomarkers for NAFLD Identified Using Proteomics

- Presenting several biomarkers identified using proteomics which successfully track disease progression including ones which can discriminate healthy individuals from NAFL, NAFL from NASH and the stages of lobular inflammation
- Sharing the first antibody-free serum protein biomarker assay and progress in developing a rapid point-of-care test (POCT)
- Improving biomarker detection and quantification using a universal calibration mix which can be used for any protein biomarker and up to six different biomarkers in a single acquisition

14.10 Can Biomarker Technologies be used to Predict Fibrosis Progression for Population Enrichment?

- Panel Discussion & Q&A for Preceding Speakers

14.30 Afternoon Break & Networking

Contextualising NASH in a Clinical Framework: Strategising Payer & Reimbursement Landscape

Vincenzo Costigliola
Founder & President
European Medical Association (EMA)

15.10 Establishing Relationship Between Doctor's Needs & Pharma's Objectives

- Representing the interests of doctors in Europe
- Aligning clinical appetite with the direction of pharma

Jeanette Kusel
Director Scientific Advice
National Institute for Health & Care Excellence (NICE)

15.30 Considerations from NICE on how to Assess the Value of Medicines for NASH

- How NICE makes decisions on whether new medicines should be funded by the UK NHS
- Sharing HTA thoughts on use of surrogate endpoints and pricing to account for uncertainty and resource savings
- Navigating long term uncertainty: predicting quality of life and survival

Ian Rowe University Academic Fellow & Hepatologist **University of Leeds**	**15.50 Determining the Natural History of NASH & it's Impact on Potential Cost Effectiveness** • Demonstrating the rate of progression in NASH as uncertain and current projections likely overstating the future incidence of cirrhosis • The majority of deaths in NASH relate to co-morbid diseases rather than liver-related mortality • Presenting the impact of treatments are better considered through the lens of primary and secondary prevention, as is the case for cardiovascular disease
Giampiero "GP" Carlo Head of Brand: Cotadutide, Cardiovascular, Renal & Metabolism (CVRM) **AstraZeneca**	**16.10 Navigating NASH Reimbursement – a European Conundrum?** • Presenting and discussing the patient conundrum • Evaluating the payer challenge • Determining the industry response (good and bad)
	16.30 Goal Setting in Medical Care & Insights for Earlier Pipeline Assets • Panel Discussion & Q&A with Preceding Speakers
	17.00 Chair's Closing Remarks

"The NASH landscape looks exciting with many drugs in development. Whether they are charging to and plummeting over the payer (cliff) or can hope to soar depends a lot by how well the lead candidates fare. Holding hands and supporting each other in summits like the **NASH Summit** can only help the future of NASH medications and certainly their access potential"

AstraZeneca

Conference Day Two
Friday 25th October 2019

8.20 Chair's Opening Remarks

Touching on Targets: Discussing Galectin-3, FGF21 and ROCK2 in NASH

Tariq Sethi
Co-founder
Galecto Biotech

8.30 Targeting Galectins in NASH Fibrosis

- Galectins have a potential role in the pathogenesis of fibrosis across multiple organs
- Galectin-3 is now being targeted clinically for the treatment of NASH
- The talk will focus on the challenges of targeting fibrosis and potentially metabolic effects in NASH, generally, and the evidence for Gal-3

Felix Yeh
Scientist
Genentech

8.50 The Effects of FGFR1/KLB Bi-Specific Agonist Antibody BFKB8488A in Patients with T2D

- Evaluating pharmacokinetic and pharmacodynamic responses to BFKB8488A
- Presenting how biomarker responses suggest the utility of this molecule in treating patients with NASH
- Exploring possible mechanisms of FGF21 in NASH

Nicolas Guisot
Research Fellow
RedX Pharma

9.10 Selective ROCK2 Inhibitors for the Treatment of Fibrosis

- ROCK2 is often upregulated in diseases associated with acute and chronic inflammation, including those associated with damage caused by high glucose and high fat diets
- Highly selective ROCK2 inhibitors developed by Redx scientists have demonstrated both anti-fibrotic and anti-inflammatory activity in preclinical *in vitro* and *in vivo* models of fibrosis

9.30 Collective Q&A

- Panel Discussion & Q&A with Preceding Speakers

10.00 Morning Refreshments & Networking

Combinations, Partnerships & Pediatrics: Industry Strategies for NASH

Trent Ross
Principal Scientist, Metabolism
Pfizer

10.30 Understanding the Utility of Models to Evaluate Combination Decisions

- Assessing different models in the context of Pfizer's ACC inhibitor
- Critically analysing different pathways for co-administration

Nikolai Naoumov
Executive Director, Hepatology Sciences & Innovation
Novartis

10.50 Update on the Progress in NASH Combination Therapies

- Understanding the pathogenesis and rationale for combination regimes in NASH
- New developments and what we learned in 2019
- Exploring combination options in clinical studies and future outlook

Michel de Baar
Executive Director – Business Development, Licensing, Infectious Diseases, Vaccines, Cardiovascular & Metabolic Diseases
MSD

11.10 How Big Pharma Look at NASH

- Presenting NASH from a "big pharma" perspective and the opportunity it provides
- Evaluating treatment modalities for NASH from the perspective of seeking partnerships
- Analysing where the field is moving to

Naim Alkhouri
Director of the Metabolic Health Centre
Texas Liver Institute

11.30 The Optimal Design of Pediatric NASH Trials: From Early Proof-Of-Concept to Late Phase 2 Trials
- Similarities and differences between pediatric and adult NASH
- Designing a successful NASH trial in children from a family to physician to industry perspectives

11.50 What Types of Combination Studies Should be Being Done?
- Panel Discussion & Q&A with Preceding Speakers

12.30 Lunch & Poster Session

Reviewing Clinical Advances & Regulatory Guidelines from the Last 12 Months

Peter Traber
Partner
Alacrita Consulting

13.30 NASH, Now: Therapeutic Targets & the Competitive Clinical Trial Landscape
- Discussing how current clinical experience and understanding can influence the next generation of R&D and commercialisation decisions
- Overview of clinical compounds being evaluated for NASH with emphasis on mechanistic differences
- Evaluating regulatory guidance on development of NASH therapeutics with focus on histology versus non-invasive imaging in drug advancement

Frank Anania
Division of Gastroenterology & Inborn Errors Products
FDA

13.50 Regulatory Guidance for NASH with Compensated Cirrhosis
- Re-assessment of liver biopsy tissue from cirrhotic liver to serve as a reliable surrogate endpoint in clinical trials for compensated cirrhosis
- Consideration of time to clinical decompensatory events versus the time to completion of both phase 3 and phase 4 studies in the Subpart H regulatory pathway for full market approval in the USA
- Provide indications and additional data on new agents used for non-cirrhotic indications in the field of NASH

Richard Torstenson
Director International Clinical Development NASH
Allergan

14.10 The Impact of the First Approved NASH Drug on Phase 3 Design
- Evaluating clinical and regulatory considerations for future trial design in NASH, specifically post approval of NASH treatments
- Discussing the utility of biomarkers to facilitate drug development

14.30 Discussing Clinical Development in NASH Cirrhosis
- Panel Discussion & Q&A with Preceding Speakers

15.00 Afternoon Break & Networking

Aligning Drug Development with Patients Needs

Livia Alimenia
European Office Director
Global Liver Institute

15.30 Regulatory Initiatives to Advance Patients Goals
- Outlining the key initiatives of the Global Liver Institute and NASH Council in Europe
- Presenting a global perspective on initiatives to align patient interests with drug development in NASH

Achim Kautz
Founder
Leberhilfe Projekt

15.50 The Patient Perspectives on Future Therapeutic Options in NASH & Patient Needs
- Discussing the diversity of interdisciplinary management
- Focusing on quality of life of NASH patients
- Evaluating clinical appetite for sustainable life style change

16.10 Discussing Patients Perspectives & How to Improve Clinical Trial Participation
- Panel Discussion & Q&A with Preceding Speakers

16.30 Chair's Closing Remarks

Partnership Opportunities

The **3rd NASH Summit Europe** is your fastest route to European organisations prioritising NASH drug development, and a networking experience like no other NASH conference.

As an exclusive gathering of NASH stakeholders this will be your opportunity to interact with your industry peers, generate business leads and solidify relationships with over 80 NASH drug developers. This is your opportunity to elevate your company's standing and influence industry's thinking in Europe.

As the 2020 NASH drug development landscape brings first time, new challenges for combination drug development and clinical trial design, demonstrate your capabilities, build new connections, further cement partnerships and outcompete your competitors.

Contact us today to find our more and partner with the **3rd NASH Summit Europe** **sponsor@hansonwade.com**

Delegate Seniority Breakdown



Total Breakdown of Audience by Industry



*Based on market research and previous NASH Summit statistics

Program Partner

www.metabolon.com

Metabolon, Inc. is the world's leading health technology company advancing metabolomics for precision medicine and life sciences research. Its Precision Metabolomics™ is a powerful technology for assessing health and delivering biomarker discoveries, innovative diagnostic tests, and valuable data for genomics and population health initiatives. Metabolon's expertise is accelerating research and product development across the pharmaceutical, biotechnology, consumer products, nutrition industries, as well as academic and government organizations. The company was founded in 2000.

Spotlight Partner

www.xylyxbio.com

To develop new drugs to combat liver diseases, pharma companies need better in vitro models for compound screening and testing. Xylyx Bio's native, disease-specific extracellular matrix substrates recapitulate the disease state and enable cell models that are significantly more predictive of human pathophysiology, allowing drug candidates to be investigated in vitro in a disease-relevant environment. Xylyx Bio products comprise both the mechanical properties and complex ratios of ECM components specific and unique to each organ type and disease state and are available in a variety of 2D and 3D product formats to support high-throughput assays.

Become a Partner

Jakub Nunuk
Partnerships Manager
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways To Book

www.nash-europe.com/take-part/register

Tel: +44 (0)20 3141 8700

Email: register@hansonwade.com

1. Confidently inform decisions for combination therapy by evaluating early stage novel compounds and contextualising late stage candidates as the backbone for combination decisions
2. Understand progress with proteomics and metabolomics to identify serum biomarkers and assess their validity against liver biopsy
3. Review European clinical trial progress and learn the narrative behind regulatory guidelines for late stage NASH

SECURE YOUR PLACE

Pharma & Biotech Drug Developer Pricing	Register and Pay by Friday 23rd August 2019	Register and Pay by Friday 20th September 2019	Final Online Price
Gold: Conference + Workshop Day	£2198+ VAT **(save £300)**	£2398 + VAT **(save £100)**	£2498 + VAT
Silver: Conference Only	£1399 + VAT **(save £300)**	£1599 + VAT **(save £100)**	£1699 + VAT
Bronze: Workshop Day Only	£899 + VAT		

Standard Pricing	Register and Pay by Friday 23rd August 2019	Register and Pay by Friday 20th September 2019	Final Online Price
Gold: Conference + Workshop Day	£3098 + VAT **(save £300)**	£3298+ VAT **(save £100)**	£3398 + VAT
Silver: Conference Only	£2299 + VAT **(save £300)**	£2499 + VAT **(save £100)**	£2599 + VAT
Bronze: Workshop Day Only	£1199 + VAT		

*Academics are entitled to a 40% discount off the Pharma & Biotech Pricing (Please note: Discounts cannot be combined with any other offer)

Venue

The Waldorf Hilton
London Aldwych, London,
WC2B 4DD, United Kingdom

For further information or assistance, please visit www3.hilton.com